Danaher (DHR) Projected to Release Quarterly Earnings on Wednesday

Key Points

• Danaher is expected to report Q3 2026 results before markets open on October 21. Analysts forecast earnings of $1.92 per share and revenue of $6.56 billion.
• In the previous quarter, Danaher exceeded expectations with $1.94 in EPS and $6.26 billion in revenue, up 5.5% year over year.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $235.41, compared with a recent share price of $223.30.

Danaher (NYSE:DHR - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect Danaher to post earnings of $1.92 per share and revenue of $6.56 billion for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:00 AM ET.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The business's revenue for the quarter was up 5.5% compared to the same quarter last year. On average, analysts expect Danaher to post $8.53 EPS for the current fiscal year and $9.26 EPS for the next fiscal year.

Danaher Price Performance

Shares of NYSE:DHR opened at $223.30 on Wednesday. The firm's 50 day moving average price is $212.41 and its 200-day moving average price is $195.13. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $156.98 billion, a PE ratio of 27.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher's payout ratio is 28.42%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. UBS Group assumed coverage on shares of Danaher in a report on Wednesday, September 9th. They set a "buy" rating and a $250.00 target price for the company. Evercore reiterated an "outperform" rating and issued a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Wells Fargo & Company dropped their price target on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 16th. Finally, Morgan Stanley upped their price objective on Danaher from $220.00 to $240.00 and gave the stock an "overweight" rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average target price of $235.41.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.